Physician profile
Britt Haley Bolemon
NPI 1679593966
$5,743.86
in general payments reported to CMS, 2019-2025
51 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $226 · 2021: $471 · 2022: $420 · 2023: $998 · 2024: $1,928 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,019 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,019.24 |
| Education | $124.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $473.90 | 2019-2024 | Imdelltra (Amg 757) |
| Bayer Healthcare Pharmaceuticals INC. | $471.01 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $383.69 | 2022-2025 | Opdivo, Opdualag, Sprycel |
| Astellas Pharma US INC | $361.48 | 2019-2025 | Padcev, Xtandi |
| Galvanize Therapeutics, INC | $315.65 | 2024 | Aliya System |
| Astrazeneca Pharmaceuticals LP | $281.94 | 2019-2025 | Enhertu, Calquence |
| Beigene USA, INC. | $218.62 | 2022-2023 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $215.39 | 2020-2022 | |
| Janssen Biotech, INC. | $208.19 | 2024-2025 | Erleada, Akeega, Rybrevant |
| Merck Sharp & Dohme LLC | $179.94 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Beone Medicines USA, INC. | $167.69 | 2025 | Brukinsa |
| Mirati Therapeutics, INC. | $160.76 | 2023 | Krazati |
| Medtronic USA, INC. | $152.02 | 2019 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Medtronic, INC. | $145.81 | 2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $135.64 | 2024 | Ogsiveo |
| Novartis Pharmaceuticals Corporation | $125.48 | 2023-2025 | |
| Genmab U.S., INC. | $121.87 | 2025 | Epkinly |
| Abbvie INC. | $116.44 | 2023-2025 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $102.13 | 2021 | |
| Eisai INC. | $97.84 | 2019-2025 | |
| Puma Biotechnology, INC. | $94.35 | 2021 | |
| Pfizer INC. | $93.64 | 2024-2025 | |
| Seagen INC. | $90.48 | 2023 | Adcetris, Tukysa |
| Celgene Corporation | $87.08 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Karyopharm Therapeutics INC. | $80.73 | 2020 | |
| Apellis Pharmaceuticals, INC. | $75.56 | 2025 | Empaveli |
| Emd Serono, INC. | $70.54 | 2022-2025 | Bavencio |
| Gilead Sciences, INC. | $61.08 | 2024-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $50.20 | 2025 | Ojjaara, Blenrep |
| Genzyme Corporation | $49.56 | 2023-2025 | |
| Tersera Therapeutics LLC | $41.29 | 2025 | Zoladex, Xermelo |
| Pharmacosmos Therapeutics INC. | $37.57 | 2024-2025 | Monoferric |
| Jazz Pharmaceuticals INC. | $34.81 | 2023-2025 | |
| Array Biopharma INC | $32.91 | 2023-2024 | Lorbrena, Braftovi, Mektovi |
| Davol INC. | $30.68 | 2025 | |
| Daiichi Sankyo INC. | $27.52 | 2024 | Enhertu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.40 | 2024 | Gilotrif |
| Azurity Pharmaceuticals, INC. | $23.06 | 2025 | Danziten |
| Pharmaessentia USA Corporation | $18.50 | 2024 | Besremi |
| Adaptive Biotechnologies Corporation | $17.88 | 2024 | Clonoseq |
| Nuvation Bio INC. | $17.69 | 2025 | Ibtrozi |
| Takeda Pharmaceuticals U.S.A., INC. | $17.43 | 2025 | Iclusig |
| Sobi, INC | $16.78 | 2025 | |
| Incyte Corporation | $16.58 | 2023 | Monjuvi |
| Genentech USA, INC. | $16.55 | 2023 | Venclexta |
| Kyowa Kirin, INC. | $15.88 | 2024 | Poteligeo |
| Exelixis INC. | $13.62 | 2025 | Cabometyx |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Britt Bolemon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.